Hematology/Oncology

Top Story

Contralateral prophylactic mastectomy incidence increases among men with breast cancer

September 3, 2015

The use of contralateral prophylactic mastectomy has increased among men diagnosed with unilateral breast cancer, according to study results published in JAMA Surgery.

Further, contralateral prophylactic mastectomy (CPM) occurred more frequently among younger patients, white men and patients with private insurance, the researchers reported.

In the Journals

Curettage suggested as first treatment for tumorinduced osteomalacia lesions in long bone

September 3, 2015
As researchers of this retrospective study of 17 patients with tumor-induced osteomalacia lesions in long bones found 82% of tumors were located in the epiphysis, they…
FDA News

FDA grants breakthrough therapy designation, priority review to Opdivo for nonsquamous NSCLC

September 3, 2015
The FDA granted breakthrough therapy designation and priority review to nivolumab for the treatment of patients with nonsquamous non–small cell lung cancer who…
In the Journals

Model helps predict long-term survival after surgery in patients with malignant mesothelioma

September 3, 2015
A prognostic model appeared to help predict long-term survival in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy, according to…
In the Journals

Imetelstat demonstrates clinical activity for myelofibrosis, but may cause myelosuppression

September 2, 2015
The telomerase inhibitor imetelstat demonstrates clinical activity in patients with myelofibrosis, according to the results of a pilot study.However, imetelstat (Geron…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
morganatic-roan